Grail, Inc. (NASDAQ:GRAL - Get Free Report) President Joshua J. Ofman sold 2,109 shares of the company's stock in a transaction that occurred on Friday, March 7th. The shares were sold at an average price of $31.20, for a total value of $65,800.80. Following the completion of the sale, the president now owns 559,673 shares in the company, valued at approximately $17,461,797.60. This represents a 0.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
Grail Stock Performance
Shares of GRAL stock traded up $2.82 on Friday, hitting $29.74. The company had a trading volume of 1,412,295 shares, compared to its average volume of 1,227,880. Grail, Inc. has a twelve month low of $12.33 and a twelve month high of $63.99. The company has a 50-day moving average price of $31.81 and a 200-day moving average price of $21.34.
Grail (NASDAQ:GRAL - Get Free Report) last announced its quarterly earnings results on Thursday, February 20th. The company reported ($1.86) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($4.41) by $2.55. The company had revenue of $38.25 million during the quarter, compared to analyst estimates of $35.33 million. On average, equities analysts expect that Grail, Inc. will post -15.15 EPS for the current year.
Institutional Trading of Grail
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FNY Investment Advisers LLC purchased a new stake in shares of Grail during the 4th quarter worth about $26,000. State of Tennessee Department of Treasury purchased a new position in Grail during the fourth quarter worth approximately $28,000. Lindbrook Capital LLC acquired a new stake in Grail in the fourth quarter valued at approximately $28,000. Sterling Capital Management LLC purchased a new stake in shares of Grail in the fourth quarter valued at approximately $29,000. Finally, Wellington Shields Capital Management LLC purchased a new stake in shares of Grail in the fourth quarter valued at approximately $33,000.
Analyst Upgrades and Downgrades
Separately, Morgan Stanley assumed coverage on shares of Grail in a research note on Wednesday, November 27th. They set an "equal weight" rating and a $16.00 price objective for the company.
Check Out Our Latest Stock Report on GRAL
Grail Company Profile
(
Get Free Report)
GRAIL, Inc is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.
See Also
Before you consider Grail, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Grail wasn't on the list.
While Grail currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
